Destiny: Destiny Pharma presents "exciting" data for ringworm drug

(marketscreener.com) Destiny Pharma PLC - biotechnology company, focused on developing and commercialising medicines for life-threatening infections - Announces new data on one of its XF Drug Platform compounds, XF-70, which has demonstrated potency in an in vivo model of ringworm, a common fungal skin infection. Says ringworm affects up to one in four people...https://www.marketscreener.com/quote/stock/DESTINY-PHARMA-PLC-37788317/news/Destiny-Pharma-presents-exciting-data-for-ringworm-drug-46995852/?utm_medium=RSS&utm_content=20240618